Clinical updates, including trial initiations, enrollment status and data readouts and publications: Atossa, Bergenbio, Boehringer, Harbour, Inhibrx, Novavax, Noxxon, Sanofi, Swedish Orphan, Translate.
What started with Austrian regulators suspending use of one batch of Astrazeneca plc’s COVID-19 vaccine has expanded into precautionary holds in Denmark and other EU countries as PRAC, the EMA’s safety committee, investigates whether blood clots, which have resulted in at least two deaths in Europe, are connected to the vaccine.
The U.S. FDA has granted emergency use authorization (EUA) to Breath Direct Inc. for its BDR-19 critical care ventilator for the treatment of critical care patients with respiratory insufficiency. Initial shipments of the device are expected within weeks. The EUA marks a major milestone for the fledgling Long Beach, Calif.-based company, which was started by medical device entrepreneur Darren Saravis in the early days of the pandemic.
LONDON – New research shows it is possible to diagnose Parkinson’s disease by mass spectrometry analysis of sebum samples taken with a simple skin swab, and that the same technique has potential to be used for diagnosing COVID-19. In a paper published in Nature Communications on March 11, 2021, scientists and clinicians in the U.K. and the Netherlands describe using high resolution mass spectrometry to profile the chemical signature of lipids and other biomarkers in sebum from Parkinson’s patients and show how these exhibit subtle but fundamental changes as the disease progresses.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Berlin Heart, Canam Scientific, Clordisys Solutions, Sd Biosensor, Zymo Research.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbott, Alafair Biosciences, Barm Advanced Communications, Bioventus, Certara, Ibex Medical Analytics, Integrated DNA Technologies, Iridex, Ligolab, Merit Medical Systems, Mevion Medical Systems, Microbix Biosystems, Mission Bio, MVP Health Care, Nemaura Medical, Perflow Medical, Persephone Biosciences, Proscia, Rhinostics, Roche, Shanghai Focus Healthcare, Swift Biosciences, Teleflex.
LONDON – The largest study of its kind to date has identified new biomarkers of inflammation that are both indicators of severe COVID-19 infection and distinguish it from severe influenza.
Positive COVID-19 efficacy numbers from Vir Biotechnology Inc. and Glaxosmithkline plc (GSK) has prompted them to immediately seek an emergency use authorization (EUA) with the FDA and similar authorizations in other countries for their monoclonal antibody, VIR-7831. Meanwhile, the phase III Remdacta study of Actemra/RoActemra (tocilizumab) plus Veklury (remdesivir) vs. placebo plus Veklury, from Roche Holding AG and Gilead Sciences Inc., missed its primary endpoint in treating hospitalized patients with severe COVID-19 pneumonia receiving standard of care.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alkermes, Astellas, Aveo, Biocryst, Biohaven, Bioxcel, Denali, Eli Lilly, J&J, Kadmon, Longeveron, Marius, Nouscom, Nuvation, RDIF, Spectrum.
RSS
